Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy

BACKGROUND: While novel drugs have been developed, docetaxel remains one of the standard initial systemic therapies for castration-resistant prostate cancer (CRPC) patients. Despite the excellent anti-tumor effect of docetaxel, its severe adverse effects sometimes distress patients. Therefore, it wo...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Shimpei, Kohjimoto, Yasuo, Iguchi, Takashi, Koike, Hiroyuki, Kusumoto, Hiroki, Iba, Akinori, Kikkawa, Kazuro, Kodama, Yoshiki, Matsumura, Nagahide, Hara, Isao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802623/
https://www.ncbi.nlm.nih.gov/pubmed/27001073
http://dx.doi.org/10.1186/s12894-016-0133-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802623/
https://www.ncbi.nlm.nih.gov/pubmed/27001073
http://dx.doi.org/10.1186/s12894-016-0133-y

Ejemplares similares